A retrospective study by Verma et al. reported the prevalence of NASH in patients with elevated ALT levels (>35 U/L) to be 28.9% compared to the normal ALT group, which had a frequency close to 10.7%. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.